Public Health England recently predicts that increasing antibiotic resistance could lead to 10 million deaths by 2050 worldwide, plus leading economist Lord Jim O’Neill is saying it could also cost the global economy $100 trillion by 2050. A well-respected Doctor of Microbiology has stressed the unique benefits of antimicrobial technology as part of the wider solution to cross-contamination in healthcare settings.

HM49 Dr Mike Karavolos BioCoteDr Michail Karavolos is the new technical manager at market leading antimicrobial solutions provider BioCote Ltd. He told the latest Healthcare Estates Management conference that reducing Healthcare-Associated Infections (HCAIs) and antibiotic resistance can only be achieved by NHS estate managers being more open to technology that provides innovative property solutions.

The current HCAI regime of infection prevention and control strategies (including hand hygiene, cleaning, and training procedures) has long proven to be ineffective.

Why healthcare settings pose infection risks

Dr Karavolos explains: “Healthcare settings particularly, along with other highly populated environments, are a breeding ground because of shared facilities and enclosed environments, circulated air, common contact surfaces and extended mixing.

HM49 BioCote Infection Control graphic“BioCote Antimicrobial Technology makes all kinds of surfaces inhospitable to pathogenic microorganisms. The silver ion based technology has no specific site of microbial attack, making evolution of resistance extremely difficult.
“Silver ions especially with those with high efficacy and non-toxic properties can be manufactured into a range of materials, including plastics, polymers, paints, textiles, fabrics, ceramics, paper, board and many other materials. While BioCote Technology doesn’t remove the need for regular cleaning, it is the best complementary strategy.

“BioCote Silver Ion Antimicrobial Technology has a multi-modal action and is effective against a range of leading superbugs (including MRSA and ESBL-producing E. Coli, Clostridium difficile and Klebsiella pneumonia, plus carbapenemase-producing Enterobacteriaceae or CPE).

“Along with Acinetobacter and Pseudomonas, CPE has been classed as the most ‘critical’ group of bacteria by the WHO, because it poses a threat in hospitals, nursing homes, and among patients whose care requires devices such as ventilators and blood catheters.

“CPE also encompasses the likes of Escherichia, Shigella, and Salmonella and having been evidenced to survive for many months on hard surfaces can cause severe, sometimes deadly, infections such as septicaemia and pneumonia.
“With the numbers of antibiotic resistant bacteria continuing to grow, current methods to control multi-drug resistant pathogenic bacteria are increasingly limited. However, BioCote Antimicrobial Technology can successfully combine with thorough hand-washing practices and regular cleaning to minimise cross-contamination.

“Because it does not wear out or wipe off surfaces, it can provide a continuous decontamination effect and in a ‘live’ 18-month hospital case study, BioCote antimicrobial protected materials regularly demonstrated reductions in bacteria of up to 99 per cent. Indeed, results also indicated lower numbers of bacteria on other untreated surfaces too, because there are fewer bacteria being transferred.

HM49 BioCote SuperbugsmallWith BioCote Antimicrobial Technology there are significant decreases in microbes in just 15 minutes and reductions of up to 99.5 per cent are achieved in two hours. It works continuously and will last for the functional lifetime of the product and help maximise existing hygiene processes.

It’s stable and will not negatively affect product appearance or performance, plus it’s environmentally and ecologically acceptable and completely harmless to people. It’s surprisingly cost effective and affordable too – simply integrated into any product or surface at the time of manufacture.

Plus, it’s unique in that products protected with BioCote Technology are required to deliver on the company’s self-imposed levels of antimicrobial performance before they can carry the trademark. Under a legally binding contract, BioCote specify regular and stringent quality control testing procedures for all customers. It’s also the only antimicrobial technology to be HACCP certified as food-safe and suitable for addition to food contact products.

For further information visit www.biocote.com